Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are both considered as public health problems, and they are among the major causes of mortality and morbidity, particularly in developing countries. Th e fatality of these diseases is well known; 600.000 HBV-related deaths are estimated to occur annually and 73% of all liver cancer deaths worldwide are due to hepatitis viruses, with much higher proportions in low and middle income countries 1 .
HBV has the potential to deteriorate the health seriously. With its carrier rate of 20%, it has become one of the most contagious agents threatening public health. Insuffi cient coverage of HBV vaccination, sharing blood-contaminated equipment by drug users, unsafe blood transfusions, and inadequate health precautions are major risk factors for hepatitis B virus infection in most developing countries 2, 3 .
Currently, 400 million individuals around the world are infected with hepatitis B. Approximately 40% of them are associated with cirrhosis or hepatocellular carcinoma. In addition, one third of the global population has been exposed to hepatitis B virus. Transmission routes of HBV can be classifi ed in 4 major groups; parenteral, seropozitifl iği için risk faktörü olarak bulundu. Ancak, risk faktörleri HCV seropozitifl ik oranını etkilemedi.
SONUÇ: İzmir'de HBV enfeksiyonu düșük orta derecede endemiktir. Sosyoekonomik ve çevresel risk faktörleri HBV enfeksiyonu için önemlidir.
Anahtar kelimeler: hepatit B; hepatit C; prevalans perinatal, horizontal and sexual. HBsAg infection levels have traditionally been described according to three categories of endemicity indicating the proportion of the population being seropositive for HBsAg as low (<2%), lower intermediate (2-4%), higher intermediate (5-7%) and high (≥8%) 1, 4, 5 .
Clinical manifestations of acute icteric hepatitis may develop in about 25% of cases with HCV infection. In around 70% of infected cases (range 50-85%) chronic RNA positive disease develops. Cirrhosis develops over a 20-year period. Th e possibility of developing cirrhosis is less than 5% and 20% in cases infected before and aft er 40 years of age, respectively 6 . Th e role of HCV in chronic hepatitis has gradually increased in Turkey in recent years. Ökten reported that HBV infection is still important; however contribution of HCV has risen from 23% to 38.1% during the last decade. In other words, the contribution of HBV to cirrhosis decreased from 56.6% to 45.9% and the contribution of HCV rose from 25.2% to 45.9% 7, 8 .
Prevalence of HCV infection around the world is predicted to be around 2.2-3%. Th is means that approximately 130-170 million individuals are HCV-positive worldwide North America has the lowest HCV prevalence (less than 1%), in contrary countries with high prevalence are located in Asia and Africa 6, 9 .
HBsAg is the main clinical marker indicating acute or chronic infection. Th e prevalence and the endemicity of HBV infection is defined with the presence of HBsAg
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. Antibodies against HCV are detected by sensitive and specifi c enzyme immunoassay tests to defi ne the HCV infection 10 .
Th e large reservoir of patients worldwide who are chronically infected with HBV creates an enormous disease burden 11 . Turkey is in a non-endemic area for HCV infection; however has an intermediate seroprevalence level for HBV infection. In a previous study, HBsAg and Anti-HCV antibodies were positive in 4.0% and 0.95% of the included 5471 Turkish subjects, respectively 12 . Turkish surveillance system notifi es HBV and HCV; however inadequate notifications may exist. Durusoy reported laboratory notifi cation rates of 12% and 1-4% for HBV and HCV, respectively 13 .
In this study we aimed to determine the seroprevalence rate and associated risk factors of hepatitis B and C virus infections in İzmir, Turkey.
Methods
Th is community-based cross-sectional study was conducted in İzmir located in the Aegean region of Turkey, between January and March 2010. Th e study was approved by the Ethics Committee of the İzmir Provincial Directorate of Health. All participants gave written consents before fi lling the questionnaires.
Survey design and sample size
Th e population of İzmir was 3,739,353. Th e required responding sample size was calculated using the EpiInfo computer program (Centers for Disease Control and Prevention, Atlanta, Ga., USA). Th is led to a sample size of 2737 individuals with a confi dence interval of 95%, a sample error of 2% and a design eff ect of 2, in case where the estimated seroprevalence of HBsAg was considered to be 2.5%.
Th ere were a total of 29 counties in the province. Th e size of the sample in each stratum (county) was calculated in proportion to the population. A total of 2737 healthy individuals over 14 years of age living in İzmir, selected using data from the İzmir Health Directorate by a random selection method, were determined as the target group. In cases where these individuals were inaccessible or rejected participation in the study, two substitutes for each individual were determined, again using a random selection method.
Th ere has been an HBV vaccination program for neonates in Turkey since 1998. Th is group of vaccinated young people were excluded.
Th e questionnaire included questions regarding socio-demographic characteristics (age, gender, place of abode, educational level, family size and the socioeconomic level) and risk factors related with hepatitis virus contamination.
Serology
Blood samples of 8cc were obtained from participants using the Vacuette® Standard tube holder (BD vacutainer, Becton Dickinson, UK). All samples were centrifuged and the isolated serum was stored at -20°C. Presence of HBsAg, Anti-HBs, Anti-HBc total and Anti-HCV were tested using the ELISA (Diasorin, Italy) method.
Statistical analysis
Data was evaluated using the SPSS 14.0 soft ware program. Diff erences between personal characteristics were evaluated in terms of seropositivity. In data analysis, the chi-square test was used. Multivariate logistic regression analyses were performed to identify risk factors for hepatitis B virus sero-markers. In this model, the signifi cant variables from the univariate analysis were included. p<0.05 was considered signifi cant.
Results
Socio-demographic characteristics of the 2737 participant were summarized in Table 1 . Most individuals were living in urban areas. Th e mean age was 44.05±16.83 . Most of the participants were married women graduated from elementary school. Th ey were housewives in the low income group. Th e household number was 4 (1-13).
HBsAg, Anti-HBs, Anti-HBc total and Anti-HCV were positive in 2.8% (n=85), 32.4% (n=886), 31.4% (n=860) and 0.3% (n=7) of the participants, respectively. Anti-HBc total alone (presence of Anti-HBc total in the absence of HBsAg and Anti-HBs) was found 11.8% (n=323). Th e rates of seroprevalence of hepatitis markers in gender and age groups are summarized in Graphs 1-4.
Risk factors associated with the presence of hepatic markers are summarized in Table 2 . HBsAg positivity was correlated with education, income, age and family history of hepatitis (p=0.001), history of previous hepatitis or jaundice (p<0.001), and sharing contaminated equipments (p=0.006) ( Table 2) .
Anti-HBs positivity was correlated with education, income, age, area of abode, marital status, family history of hepatitis, and history of previous hepatitis or jaundice. Anti-HBc total positivity was higher among men, those who were illiterate, and in the lower income group. It was also associated with marriage, previous hepatitis and family history of hepatitis, history of surgery, history of ear piercing, and type of sexual relationship. Anti-HBc total alone was statistically associated with male gender, education, age, income, marriage, previous hepatitis and family history of hepatitis, history of surgery and dental therapy, and history of ear piercing (Table 3) .
According to multivariate analysis, HBsAg seropositivity was higher in those illiterate, subjects with previous hepatitis history and with family history of hepatitis (Table 3 ). In addition, income, education, familial . Th e prevalence of HBsAg, Anti-HBc total and Anti-HBs was found to be 6.0%, 29.3%, and 30.3% respectively, in Malatya 21 .
History of previous hepatitis and family history of hepatitis were risk factors for having HBsAg positivity. Similar results were found in some studies conducted in developing countries 22, 23 . According to a prevalence study in Turkey, living in urban areas, living in southeastern region of Turkey, being male, having close contact with an infected person, undergoing oral and dental interventions, having a history of transfusion, begin married, and history of travel abroad are the most common risk factors for Hepatitis B transmission 12 . Kurcer reported that HBV infection was independently associated with the age of 21 or higher, illiteracy, being history of hepatitis and age were all signifi cantly associated with Anti-HBs positivity.
Male gender, illiteracy, lower income and urban residency, history of jaundice or hepatitis and family history of hepatitis were signifi cant risk factors for AntiHBc total positivity. Risk factors for Anti-HBc total alone were illiteracy, lower income, older age and previous hepatitis history.
No relationship was found between HCV prevalence and socio-demographic characteristics and risk factors.
Discussion
Th e prevalence of HBsAg of 2.8% in İzmir was in lower intermediate range. Community-based studies dealing with the rate of HBsAg in İzmir are limited. Yazan-Sertöz et al. from İzmir determined that HBsAg positivity rate in 4537 blood donors was 2.3% 14 . Afşar et al. reported that 1.38% of blood donors had HBsAg positivity 15 . Köse et al. reported that 2.2% of the barbers and hairdressing employees in İzmir were positive for HBsAg and 0.4% of them were positive for Anti-HCV 16 .
In a meta-analysis performed by Mıstık et al., the HBsAg positivity rate was reported as 5.1% in In our study, blood transfusion was not a risk factor for HBV and HCV. All blood donors in Turkey are mandatorily screened for HBV and HCV. Mandatory premarital hepatitis screening is also implemented in Turkey.
Th ere were some limitations of the study. Th e questions relating to risk factors, especially regarding sexual preference and narcotic drug use might have been answered inaccurately.
Integrating HBV vaccination into the national immunisation programs and providing safe, eff ective treatment of HBV infection were effi cient preventive measures and they were important for reducing the associated HBV-related morbidity and mortality.
Th e results indicate that the study area has a lower intermediate endemicity for HBV infection.
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farmer and worker, and having multiple sexual partners 21 . Dursun et al. determined that the highest HBV infection prevalence was in the older age group and families with a history of jaundice 24 .
Anti-HBc total alone was found in 11.8% in our study. Ramezani et al. described that occult HBV infection is characterised by the presence of HBV infection without detectable HBsAg. Th ese authors found that 2.07% of blood donors had Anti-HBc total alone 25 . Shi et al. suggested that occult HBV infection was associated with an increased risk of hepatocellular carcinoma 26 .
In our study Anti-HBs positivity was 31.4%. Esfani reported that many years aft er recovery from acute hepatitis B, Anti-HBs had fallen to undetectable levels; and aft er many years of chronic HBV infection, the HBsAg titre had decreased below the detection cut off level 27 .
Anti-HBc total alone was found in 11.8 % in our study. A few investigators have analysed Anti-HBc total alone in Turkey. Th e isolated Anti-HBc total seroprevalence rate was found to be 12.1% in Tokat 18 and 6.1% in Afyon 28 . Th ere are several explanations for an isolated Anti-HBc total positivity, such as remote HBV infection and Anti-HBs that are no longer detectable or recent recovery from acute infection or undetectable levels of HBsAg in chronically infected patients or false positives 29 .
In our study, Anti-HCV prevalence was 0.3%. Yildirim et al. determined that Anti-HCV prevalence was 2.1% among healthy individuals in Tokat
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. Anti-HCV positivity was found to be 0.6% in the south-eastern region of Anatolia 25 . Akcam et al. reported that 1.0% of people were Anti-HCV positive in rural areas of the south-western region of Turkey 30 .
HCV infection varies according to geographic regions and time. Anti-HCV seroprevalence was reported as 0.54% in a total of 1,076,495 units of blood 1 . In the study conducted in an İzmir hospital, the prevalence of Anti-HCV among blood donors was 0.42% 16 . Similarly, Yazan-Sertöz et al. found a 0.3% rate of Anti-HCV positivity among 4537 blood donors in İzmir 14 . Among blood donors, 0.35% had Anti-HCV positivity in İzmir 15 .
We could not demonstrate any factor that might play a role in HCV transmission. Similar results were found by Dursun et al. 24 . Akcam determined that Anti-HCV positivity was higher in hospitalized individuals 30 .
